Tinlarebant earns Swiss orphan drug status for Stargardt disease

Swissmedic, the Swiss Agency for Therapeutic Products, has granted orphan drug status (ODS) to tinlarebant (Belite Bio) for the treatment of Stargardt disease type 1 (STGD1), an inherited macular dystrophy for which no approved pharmacologic therapy currently exists anywhere in the world. The designation follows positive topline results from the pivotal phase 3 DRAGON trial reported in December 2025 and adds Switzerland to a growing list of jurisdictions—including the United States, the European Union, and Japan—in which tinlarebant has received expedited or orphan-tier recognition.¹

The Swissmedic decision is notable not only as a regulatory milestone but also as clinical validation of an entirely novel mechanism of action in retinal disease. Tinlarebant targets serum retinol-binding protein 4 (RBP4), the sole circulating carrier of vitamin A from the liver to the retina, with the goal of reducing the formation of bisretinoid toxins that drive photoreceptor and retinal pigment epithelium (RPE) degeneration in STGD1.²^,³ If a marketing authorization application proceeds and succeeds in Switzerland, tinlarebant would become the first approved treatment for STGD1 globally.

The phase 3 DRAGON trial: Design and efficacy findings

The DRAGON trial was a 24-month, randomized (2:1, active: placebo), double-masked, placebo-controlled, global, multi-center, pivotal phase 3 trial in adolescent STGD1 patients. A total of 104 patients ranging from ages 12 to 20 were enrolled (n=69 in the Tinlarebant arm and n=35 in the placebo arm). All patients had been diagnosed with STGD1 with at least 1 mutation identified in the ABCA4 gene, an atrophic lesion size within 3 disc areas (7.62 mm²), and a best corrected visual acuity (BCVA) of 20/200 or better.

The primary efficacy endpoint was the annualized growth rate of atrophic lesions, specifically the area of definitely decreased autofluorescence (DDAF) in the study eye as measured by fundus autofluorescence (FAF) imaging—an established, validated biomarker for progressive retinal atrophy in STGD1.⁴^,⁵ The DRAGON trial met its primary endpoint: tinlarebant produced a statistically significant 35.7% reduction in the DDAF growth rate compared with placebo (P=.0033; prespecified mixed-model repeated measures analysis).¹^,⁴ A comparable treatment effect was observed in the fellow eye, with a 33.6% reduction (P=.041).⁴

The key secondary endpoint—the growth rate of the total decreased autofluorescence (DAF) area, encompassing both definitely and questionably decreased autofluorescence—also reached statistical significance. DAF growth was reduced by 33.7% in the study eye (P=.027) and 32.7% in the fellow eye (P=.017).⁴ Pharmacodynamically, the 5 mg daily dose reduced circulating RBP4 by approximately 80% from baseline, with levels returning toward baseline following drug cessation.⁴

Notably, BCVA remained largely stable over 24 months in both treatment and placebo arms, a finding consistent with the expected natural history of disease at this early lesion stage, where structural damage precedes functional decline.⁵ That bilateral symmetry in the treatment effect—observed across both primary and key secondary endpoints—was highlighted by investigators as meaningful, given that only the study eye was the pre-specified analysis target.

Safety and tolerability

Across both prior phase 2 work and the phase 3 DRAGON trial, the safety profile of tinlarebant has been consistent and mechanism-aligned.⁶^,⁷ In DRAGON, the most commonly reported drug-related adverse events were xanthopsia (a yellowish tint to vision) and delayed dark adaptation, both predominantly mild in severity and attributable to the drug's intended reduction of circulating retinol.⁴^,⁵ These effects, which were anticipated based on the mechanism of action, were largely self-limited and did not require discontinuation in most patients. Four discontinuations were treatment-related across the 24-month trial duration.⁴ No drug-related non-ocular discontinuations were reported.⁵

These findings are broadly consistent with data from the completed phase 1b/2 study (NCT05266014), in which 11 adolescents received tinlarebant 5 mg daily for 28 days followed by a 2-year extension. Delayed dark adaptation and xanthopsia were the predominant drug-related adverse events—both mild and reversible, typically resolving within 10 minutes of waking—and no severe adverse events were reported.⁶ The 24-month phase 2 extension further confirmed a sustained and reversible reduction of RBP4 with a stable mild safety profile.⁷

Clinicians should nonetheless note that sustained suppression of circulating retinol delivery to the eye, while intentional therapeutically, may carry long-term risks not yet fully characterized in longer-duration or larger populations. The safety dataset from a 104-patient, 24-month trial, while sufficient to support a registration submission in a rare disease context, limits full confidence in rare adverse events and long-term systemic implications.

Clinical context: A disease without approved treatment

STGD1 is the most common form of inherited juvenile macular degeneration, with an estimated prevalence of approximately 1 in 8,000 to 10,000 individuals.⁸^,⁹ It is caused by biallelic pathogenic variants in the ABCA4 gene, which encodes an ATP-binding cassette transmembrane transporter involved in retinoid recycling within photoreceptor outer segment discs.¹⁰ More than 1,200 disease-causing ABCA4 variants have been identified, contributing to substantial phenotypic heterogeneity.¹¹ Onset of symptoms most commonly occurs in the first or second decade of life, and the disorder progresses to a level consistent with legal blindness in many affected individuals, with near-total loss of central vision and preservation of peripheral vision as the typical trajectory.⁸

The disease is characterized by progressive accumulation of lipofuscin bisretinoids—most prominently A2E (N-retinylidene-N-retinylethanolamine)—within RPE cells, resulting in RPE dysfunction and subsequent photoreceptor degeneration.¹⁰^,¹¹ Funduscopically, a beaten-bronze macular appearance with perifoveal flecks and progressive central atrophy is typical, with fundus autofluorescence demonstrating atrophic zones of definitely decreased autofluorescence that expand over time.⁸

Until now, management has been restricted to supportive measures, including low-vision aids and avoidance of high-dose vitamin A supplementation, with no approved disease-modifying pharmacotherapy.⁸ Gene therapy approaches targeting ABCA4 remain in early clinical investigation but face the challenge of delivering an unusually large gene payload to the retina.¹¹ Tinlarebant represents a pharmacologic approach upstream of that challenge, targeting the supply of retinol substrate rather than the defective transporter.

Drug and mechanism background

Tinlarebant (also known as LBS-008) is a small-molecule, orally bioavailable non-retinoid antagonist of RBP4. RBP4 is the sole circulating carrier of all-trans retinol from hepatic stores to peripheral tissues, including the RPE.²^,³ In plasma, retinol circulates as a ternary complex with RBP4 and transthyretin (TTR); the TTR association prevents renal clearance by increasing the molecular weight of the complex. Tinlarebant disrupts the RBP4-TTR interaction, promoting renal elimination of monomeric RBP4 and thereby reducing circulating serum retinol.²^,³ This in turn limits the substrate available for the visual cycle within the RPE, where retinol is oxidized to retinaldehyde and ultimately enters the biochemical cascade that produces bisretinoids under the dysfunctional ABCA4 environment.¹⁰

The RPE expresses a specific RBP4 receptor, STRA6, which mediates cellular uptake of retinol from circulating RBP4 and is not expressed by most other peripheral tissues. This selectivity provides a theoretical basis for preferential reduction of retinol delivery to the retina without broadly compromising systemic vitamin A homeostasis, though the full long-term implications of chronic RBP4 suppression in a developing adolescent population remain under investigation.³

RBP4 inhibition as a therapeutic strategy was identified as a priority for clinical development in STGD1 and geographic atrophy (GA) by the UK National Institute for Health Research (NIHR) in a 2018 systematic review that screened nearly 8,000 articles on treatments for dry AMD and STGD1, concluding that prevention of bisretinoid accumulation was among the most promising approaches.² Belite Bio is also evaluating tinlarebant in GA (advanced dry AMD) via the phase 3 PHOENIX trial. A parallel DRAGON II study (NCT06388083; phase 2/3) is ongoing in Japan and other regions, with primary completion estimated in late 2027.

What the Swiss designation means in practice

Swissmedic's ODS framework targets conditions affecting fewer than 5 in 10,000 persons in Switzerland.¹² The designation triggers several regulatory and financial incentives: extended document protection of 15 years (compared with the standard 10 years), eligibility for accelerated review timelines, potential fee reductions including possible waiver of the flat-rate marketing authorization application fee, and potential access to Swissmedic's Early Access Pathway, which allows patients to receive critical treatments before full marketing authorization is granted.¹²

For Belite Bio, the designation strengthens its regulatory posture in a key European market at a pivotal moment. The company has indicated it expects to file a New Drug Application (NDA) with the US FDA in the second quarter of 2026, with a potential approval decision anticipated in the first quarter of 2027, based on analyst reports following the DRAGON readout.¹^,⁴ The company also holds Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the United States; Orphan Drug Designation in the US, EU, and Japan; and Sakigake (Pioneer Drug) Designation in Japan for STGD1.¹^,⁴

Analytical and interpretive considerations

The DRAGON trial result is a genuine and meaningful clinical signal in a disease that has, for more than a century since Karl Stargardt's initial 1909 description, lacked any approved pharmacologic intervention. A 35.7% reduction in the rate of DDAF lesion expansion, with P = .0033 on a prespecified primary analysis, meets the threshold for statistical significance and, critically, was supported by concordant effects on the key secondary endpoint and in the fellow eye—reducing the likelihood that the primary result represents a chance finding.

Nevertheless, several limitations warrant careful consideration. The trial enrolled 104 subjects, consistent with the size feasible in an ultra-rare pediatric population, but limited in absolute terms for characterizing the full safety profile. The primary endpoint—atrophic lesion growth by FAF—is a structural biomarker that has not yet been formally validated as a surrogate for clinically meaningful visual function outcomes in STGD1; BCVA did not significantly differ between groups at 24 months, though this is consistent with the expected natural history in patients with limited baseline lesion size. The functional consequences of slowing lesion expansion by roughly one-third, expressed in terms of preservation of reading acuity or visual field over a decade, remain to be characterized.

Next steps

Belite Bio has indicated plans to submit an NDA to the FDA in the second quarter of 2026 and is engaging regulatory authorities across multiple geographies to define parallel submission pathways. The DRAGON II trial (NCT06388083) continues to enroll, expanding the evidence base for tinlarebant in STGD1 subjects in Japan and other regions. Additional clinical data from the PHOENIX trial in geographic atrophy secondary to dry AMD will determine whether the bisretinoid-reduction strategy translates across the broader spectrum of RBP4-mediated retinal degeneration. Full peer-reviewed publication of the DRAGON pivotal data—and the accompanying subgroup, safety, and pharmacodynamic analyses—will be essential for independent clinical evaluation before widespread adoption.

References

1. Belite Bio, Inc. Belite Bio receives orphan drug status for tinlarebant in Stargardt disease in Switzerland. GlobeNewswire. May 18, 2026. https://www.globenewswire.com/news-release/2026/05/18/3296997/0/en/Belite-Bio-Receives-Orphan-Drug-Status-for-Tinlarebant-in-Stargardt-Disease-in-Switzerland.html

2. Belite Bio, Inc. Ophthalmology pipeline and mechanism of action. Belite Bio corporate website. Accessed May 19, 2026. https://belitebio.com/ophthalmology/

3. Zhong M, Kawaguchi R, Kassai M, Sun H. Retinoid homeostasis and beyond: how retinol binding protein 4 contributes to health and disease. Nutrients. 2022;14(6):1236. doi:10.3390/nu14061236. https://pubmed.ncbi.nlm.nih.gov/35334893/

4. Belite Bio, Inc. New hope for people living with a disease once deemed untreatable: Belite Bio announces positive topline results from the pivotal global, phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease. GlobeNewswire. December 1, 2025. https://www.globenewswire.com/news-release/2025/12/01/3196793/0/en/New-Hope-for-People-Living-with-a-Disease-Once-Deemed-Untreatable-Belite-Bio-Announces-Positive-Topline-Results-from-the-Pivotal-Global-Phase-3-DRAGON-Trial-of-Tinlarebant-in-Adole.html

5. Nguyen QD. Phase 3 DRAGON study for adolescent Stargardt disease [interview]. Ophthalmology Times Europe. February 24, 2026. https://europe.ophthalmologytimes.com/view/tinlarebant-phase-3-dragon-study-for-adolescent-stargardt-disease

6. Grigg JR, Chen FK, Chen TC, et al. A phase 1b/2 study of the safety and tolerability of tinlarebant in adolescent STGD1 subjects. Invest Ophthalmol Vis Sci. 2022;63(7):3518. https://iovs.arvojournals.org/article.aspx?articleid=2781626

7. Grigg JR, Chen F, Chen TC, et al. Safety, tolerability, and efficacy of tinlarebant from the 24-month phase 2 study in adolescent patients affected by Stargardt disease. Invest Ophthalmol Vis Sci. 2024;65(7):1026. https://iovs.arvojournals.org/article.aspx?articleid=2797066

8. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30. doi:10.1136/bjophthalmol-2016-308823. Note: Cited for clinical overview; direct link to the original article available at https://bjo.bmj.com/content/101/1/25

9. Runhart EH, Sangermano R, Cornelis SS, et al. The common ABCA4 variant p.(Asn1868Ile) strikingly aggravates the phenotype of Stargardt disease. Ophthalmology. 2018;125(9):1377-1387. doi:10.1016/j.ophtha.2018.01.004. https://www.aaojournal.org/article/S0161-6420(18)30045-X/abstract

10. Sparrow JR, Gregory-Roberts E, Yamamoto K, et al. The bisretinoids of retinal pigment epithelium. Prog Retin Eye Res. 2012;31(2):121-135. doi:10.1016/j.preteyeres.2011.12.001. https://pubmed.ncbi.nlm.nih.gov/22209824/

11. Georgiou M, Fujinami K, Michaelides M. Stargardt disease: transition from basic science to clinical trial. Prog Retin Eye Res. 2021;83:100899. doi:10.1016/j.preteyeres.2020.100899. https://pubmed.ncbi.nlm.nih.gov/33388388/

12. Swissmedic. Orphan Drug Designation (ODS) guidance. Regulatory Affairs News summary. January 19, 2025. https://www.regulatoryaffairsnews.com/post/swissmedic-guidance-orphan-drug-designation-ods; and Swissmedic official documentation: https://www.swissmedic.ch/swissmedic/en/home/kpa/aktuell-kpa/zl-kpa-2025.html

13. ClinicalTrials.gov. Phase 3 DRAGON trial: a study to evaluate the efficacy and safety of tinlarebant in subjects with Stargardt disease. NCT05244304. https://clinicaltrials.gov/study/NCT05244304

14. ClinicalTrials.gov. DRAGON II: a phase 2/3 study to evaluate the efficacy and safety of tinlarebant in subjects with Stargardt disease. NCT06388083. https://clinicaltrials.gov/study/NCT06388083

15. Mata NL, Choi EJ, Bui TV, et al. Evidence for in vivo differential regulation of counter-regulatory factors and inhibition of 11-cis-retinyl palmitate biosynthesis by retinoids. Retina. 2013;33(3):498-507. doi:10.1097/IAE.0b013e31825kin. Note: Cited as context for prior RBP4 antagonism work with fenretinide in geographic atrophy; verify full citation details at PubMed. https://pubmed.ncbi.nlm.nih.gov/23296070/